宫切除性神经内分泌癌的多模式治疗
Carmine Valenza1,2, Francesca Spada3, Francesco Multinu4
1Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Via Ripamonti, Milan, Italy.
Endocrine-related cancer
|July 10, 2023
概括
这项关于子宫非转移性神经内分泌癌 (NECC) 的研究发现,多模式治疗,包括手术和化疗,至关重要. 先进的FIGO阶段和盆腔放射疗法,特别是臂疗法,显著改善了生存结果.
科学领域:
- 妇科瘤学 妇科瘤学
- 神经内分泌瘤 神经内分泌瘤
- 辐射瘤学 辐射瘤学
背景情况:
- 宫非转移性神经内分泌癌 (NECC) 是一种罕见的,侵袭性的妇科恶性瘤.
- 由于前性数据有限,NECC的最佳多式联络治疗策略仍未确定.
研究的目的:
- 评估非转移性NECC患者的临床结果,这些患者接受了手术和 (新) 辅助化疗.
- 在NECC中确定影响无事件和整体生存的预后因素.
主要方法:
- 在2003年至2021年期间治疗的27名非转移性NECC患者的回顾性分析.
- 评估手术,基于的化疗 (新辅助剂/辅助剂) 和盆腔放射治疗 (EBRT +/- 支臂疗法).
- 基于预后因素的无事件生存 (EFS) 和总生存 (OS) 的评估.
主要成果:
- 在 (新) 辅助化疗期间没有发生进展或复发.
- 中位数EFS为21.1个月,中位数OS为33.0个月.
- 病理性FIGO阶段≥IIB,带或不带支臂治疗的EBRT是EFS的独立预后因素. 支臂疗法也影响了OS.
结论:
- 非转移性NECC需要多模式治疗方法,主要以FIGO阶段为指导.
- 建议考虑使用支臂疗法,特别是在局部先进的NECC.
- 由于数据稀缺,多学科瘤委员会讨论对于个性化治疗策略至关重要.
更多相关视频
05:52Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
11.5K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
204
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
204
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
